BY LATER LINES , CML STOPS BEING THE “ GOOD CANCER ” 1 , 2
Current standard-of-care treatments target the ATP-binding site on BCR-ABL1 . 3 Later lines of CML may be associated with increased resistance and intolerance . 1 , 2
LEARN MORE AT TARGETCML . COM
ATP , adenosine 5 ’ -triphosphate ; CML , chronic myeloid leukemia .
References : 1 . Soverini S , Gnani A , Colarossi S , et al . Blood . 2009 ; 114 ( 10 ): 2168-2171 . 2 . Iacob RE , Zhang J , Gray NS , Engen JR . PLoS One . 2011 ; 6 ( 1 ): e15929 . 3 . Soverini S , Mancini M , Bavaro L , et al . Mol Cancer . 2018 ; 17 ( 1 ): 49 .
Novartis Pharmaceuticals Corporation |
|
|
|
|
East Hanover , New Jersey 07936-1080 |
© 2021 Novartis |
Printed in USA |
10 / 21 |
148538-2 |